Disseminated Enteroviral Infection Associated with Obinutuzumab

Two cases of disseminated enteroviral infection occurred in patients who received the CD20 monoclonal antibody obinutuzumab. Clinical features included hepatitis, edema, and a dermatomyositis-like syndrome. These manifestations may be unfamiliar to clinicians and are possibly responsive to intraveno...

Descripción completa

Detalles Bibliográficos
Autores principales: Dendle, Claire, Gilbertson, Michael, Korman, Tony M., Golder, Vera, Morand, Eric, Opat, Stephen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Centers for Disease Control and Prevention 2015
Materias:
Dispatch
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4550142/
https://www.ncbi.nlm.nih.gov/pubmed/26291712
http://dx.doi.org/10.3201/eid2109.150104
_version_ 1782387411825721344
author Dendle, Claire
Gilbertson, Michael
Korman, Tony M.
Golder, Vera
Morand, Eric
Opat, Stephen
author_facet Dendle, Claire
Gilbertson, Michael
Korman, Tony M.
Golder, Vera
Morand, Eric
Opat, Stephen
author_sort Dendle, Claire
collection PubMed
description Two cases of disseminated enteroviral infection occurred in patients who received the CD20 monoclonal antibody obinutuzumab. Clinical features included hepatitis, edema, and a dermatomyositis-like syndrome. These manifestations may be unfamiliar to clinicians and are possibly responsive to intravenous immunoglobulin. Clinicians should remain vigilant for enteroviral infections in patients receiving obinutuzumab.
format Online
Article
Text
id pubmed-4550142
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Centers for Disease Control and Prevention
record_format MEDLINE/PubMed
spelling pubmed-45501422015-09-01 Disseminated Enteroviral Infection Associated with Obinutuzumab Dendle, Claire Gilbertson, Michael Korman, Tony M. Golder, Vera Morand, Eric Opat, Stephen Emerg Infect Dis Dispatch Two cases of disseminated enteroviral infection occurred in patients who received the CD20 monoclonal antibody obinutuzumab. Clinical features included hepatitis, edema, and a dermatomyositis-like syndrome. These manifestations may be unfamiliar to clinicians and are possibly responsive to intravenous immunoglobulin. Clinicians should remain vigilant for enteroviral infections in patients receiving obinutuzumab. Centers for Disease Control and Prevention 2015-09 /pmc/articles/PMC4550142/ /pubmed/26291712 http://dx.doi.org/10.3201/eid2109.150104 Text en https://creativecommons.org/licenses/by/4.0/This is a publication of the U.S. Government. This publication is in the public domain and is therefore without copyright. All text from this work may be reprinted freely. Use of these materials should be properly cited.
spellingShingle Dispatch
Dendle, Claire
Gilbertson, Michael
Korman, Tony M.
Golder, Vera
Morand, Eric
Opat, Stephen
Disseminated Enteroviral Infection Associated with Obinutuzumab
title Disseminated Enteroviral Infection Associated with Obinutuzumab
title_full Disseminated Enteroviral Infection Associated with Obinutuzumab
title_fullStr Disseminated Enteroviral Infection Associated with Obinutuzumab
title_full_unstemmed Disseminated Enteroviral Infection Associated with Obinutuzumab
title_short Disseminated Enteroviral Infection Associated with Obinutuzumab
title_sort disseminated enteroviral infection associated with obinutuzumab
topic Dispatch
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4550142/
https://www.ncbi.nlm.nih.gov/pubmed/26291712
http://dx.doi.org/10.3201/eid2109.150104
work_keys_str_mv AT dendleclaire disseminatedenteroviralinfectionassociatedwithobinutuzumab
AT gilbertsonmichael disseminatedenteroviralinfectionassociatedwithobinutuzumab
AT kormantonym disseminatedenteroviralinfectionassociatedwithobinutuzumab
AT goldervera disseminatedenteroviralinfectionassociatedwithobinutuzumab
AT moranderic disseminatedenteroviralinfectionassociatedwithobinutuzumab
AT opatstephen disseminatedenteroviralinfectionassociatedwithobinutuzumab

Ejemplares similares